Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1400-1409.doi: 10.12092/j.issn.1009-2501.2026.10.011

Previous Articles    

Research progress on enhancement of immunotherapy sensitivity of lung cancer by PD-1/PD-L1 pathway with traditional Chinese medicine and natural products

Siyuan ZHANG(), Xiangqi WANG, Yi YIN()   

  1. The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China
  • Received:2025-12-17 Revised:2026-03-25 Online:2026-10-26 Published:2026-11-11
  • Contact: Yi YIN E-mail:1370967149@qq.com;413672306@qq.com

Abstract:

Lung cancer (LC) is a globally prevalent type of cancer, mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More than 50% of NSCLC patients have developed metastasis at the initial diagnosis, resulting in limited treatment options for advanced stages. Immunotherapy has become the major breakthrough, among which PD-1/PD-L1 inhibitors block the binding between PD-1 and PD-L1, restore T cell activity, and inhibit tumor immune escape. Natural product-derived PD-1/PD-L1 inhibitors (PDNP) have the advantages of good oral bioavailability, strong tissue permeability, and low cost, and can regulate the tumor microenvironment and enhance the sensitivity of immunotherapy. This review summarizes the latest progress of PDNP in the treatment of LC, including flavonoids, alkaloids, terpenoids and other types of compounds. These compounds exert anti-lung cancer effects by directly or indirectly regulating the PD-1/PD-L1 pathway: directly blocking the binding of PD-1 and PD-L1; regulating upstream signaling pathways such as Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3), nuclear factor kappa B (NF-κB), and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR); and indirectly regulating the activation state of the PD-1/PD-L1 pathway by modulating the tumor microenvironment. In addition, this review discusses the anti-lung cancer effects of various traditional Chinese medicines and their active ingredients in regulating the PD-1/PD-L1 pathway, as well as the mechanism of synergistically reducing chemotherapy drug resistance. It aims to provide new ideas for lung cancer treatment and reversing drug resistance, and also offer useful references for the development of new anti-lung cancer drugs.

Key words: PD-1/PD-L1, immunotherapy, traditional Chinese medicine, natural product, lung cancer

CLC Number: